Japan Lifeline Determines Matters Related to Acquisition of Own Shares
and Cancellation of Own Shares (Acquisition of Own Shares Under the Provisions of the Articles of Incorporation Pursuant to the Provisions of Article 165, Paragraph (2) of the Companies Act and Cancellation of Own Shares Under the Provisions of the Article 178 of the Same Act)
Japan Lifeline Co., Ltd. ("the Company") announced that at the Board of Directors meeting held today, it has resolved to repurchase its own shares pursuant to the provisions of Article 156 of the Companies Act, as applied by replacing the relevant terms pursuant to the provisions of Article 165, paragraph (3) of the same Act, and cancel its own shares pursuant to the provisions of Article 178 of the same Act.
Reason for acquisition and cancellation of own shares
Given the status of funds and stock price of the Company, it has determined to repurchase and cancel its own shares as part of its shareholder return policy to improve capital efficiency.
Details of matters related to acquisition
(1)
Class of shares to be
: Common shares of the Company
acquired
(2)
Total number of shares to
: 2,500,000 shares (maximum)
be acquired
(3.1% of the total number of shares issued excluding own shares)
(3)
Total amount of shares
: 3,500,000,000 yen (maximum)
acquisition costs
(4)
Acquisition period
: February 28, 2022 to August 31, 2022
(5)
Acquisition method
: Market purchase on the Tokyo Stock Exchange
3. Details of matters related to cancellation
(1)
Class of shares to be
: Common shares of the Company
cancelled
(2)
Total number of shares to
: All of own shares to be acquired in accordance with 2. above
be cancelled
(3)
Date of cancellation
: September 16, 2022
(Note) The number of shares to be cancelled will be announced later upon completion of the acquisition of own shares as described in 2. above.
(Reference) Own shares holdings as of January 31, 2022
1
Total number of shares issued excluding
: 80,420,435 shares
own shares
Number of own shares
: 4,999,541 shares
(Note) The Company has introduced a BIP (Board Incentive Plan) trust, and the Company shares held by the trust are treated as own shares.
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on 25 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2022 06:41:07 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
